We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Therapeutic plasma exchange for refractory vaccine‐induced immune thrombotic thrombocytopenia.
- Authors
Fan, Sheng‐Bin; Tsai, Ming‐Ju; Kuo, Mei‐Chuan; Chuang, Cheng‐Hao
- Abstract
His consciousness and thrombocytopenia improved gradually, and he was extubated smoothly on the 16th day; however, on day 21, recurrent thrombocytopenia and newly developed thromboembolic events including pulmonary embolism and consciousness disturbance occurred. Dear Editor, Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare and life-threatening complication after adenoviral-vectored COVID-19 vaccination, with a reported incidence rate of 3.83 per million vaccine doses in the United States.1 Current consensus embraces management strategies including non-heparin anticoagulant and high-dose intravenous immunoglobulin (IVIG)2; however, a few patients are refractory to standard management and progress to catastrophic outcomes.3 Therapeutic plasma exchange (TPE) appears a potential salvage therapy although the efficacy remains debatable. Excellent responses in terms of improved consciousness, stabilized oxygen saturation, and resolution of thrombocytopenia were noted, although thrombocytopenia and consciousness disturbance recurred on day 33, accompanying acute kidney injury.
- Subjects
PLASMA exchange (Therapeutics); IDIOPATHIC thrombocytopenic purpura; SINUS thrombosis; REFRACTORY materials; VENOUS thrombosis; INTRACRANIAL hemorrhage
- Publication
Kaohsiung Journal of Medical Sciences, 2022, Vol 38, Issue 8, p804
- ISSN
1607-551X
- Publication type
Article
- DOI
10.1002/kjm2.12549